Kids Travel Sickness
FDA Label NDC 64997-050

Full FDA labeling including Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Keysun Pty. Limited Also Traded As Keysun Laboratories for the product Kids Travel Sickness (NDC 64997-050). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding inactive ingredient, otc - active ingredient, otc - purpose, warnings, otc - keep out of reach of children, dosage & administration, storage and handling, indications & usage, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Inactive Ingredient

Non-Active Ingredients

Isomalt, Natural Strawberry Flavour,

Natural Colour Carmine E120 (Cochineal).

Otc - Active Ingredient

Each Lozenge Contains

Cocculus 30C, Nux Vomica 30C,

Borax 6C in equal quantities

Otc - Purpose

Indications

For natural temporary relief of

motion sickness and nausea

Warnings

Warning: If symptoms persist or worsen suddenly, consult your health-care

specialist.

Otc - Keep Out Of Reach Of Children

Keep this and all other medicine out of the reach of children.

Dosage & Administration

Directions

For best results, begin taking one Kids Travel Sickness

15-20 minutes before travel. The lozenge should be licked

or sucked and does not need to be finished as the

therapeutic benefit will be gained in the first few licks.

If on a long journey, suck another lozenge if needed. Not

to be used in children under 2 years of age without medical advice.

Recommended dosage up to 3 per day.

Storage And Handling

STORE BELOW 30 C

Indications & Usage

Indications

For natural, temporary relief of motion sickness

and nausea

Package Label.Principal Display Panel

Copy Of Label (Travelsick Label)

Copy Of Label (Travelsick Label)

* Please review the disclaimer below.